NASDAQ:PRLD Prelude Therapeutics Q4 2024 Earnings Report $0.93 +0.01 (+0.94%) As of 12:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Prelude Therapeutics EPS ResultsActual EPS-$0.38Consensus EPS -$0.49Beat/MissBeat by +$0.11One Year Ago EPSN/APrelude Therapeutics Revenue ResultsActual Revenue$4.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APrelude Therapeutics Announcement DetailsQuarterQ4 2024Date3/10/2025TimeBefore Market OpensConference Call DateMonday, March 10, 2025Conference Call Time7:00AM ETUpcoming EarningsPrelude Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Prelude Therapeutics Earnings HeadlinesPrelude Therapeutics to Participate in Citizens Life Sciences ConferenceMay 1 at 7:30 AM | globenewswire.comJMP Securities Reiterates Market Outperform Rating for Prelude Therapeutics (NASDAQ:PRLD)May 1 at 2:27 AM | americanbankingnews.comTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.May 2, 2025 | Paradigm Press (Ad)Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer TherapiesApril 30 at 2:49 AM | msn.comPrelude Therapeutics (NASDAQ:PRLD) and Dianthus Therapeutics (NASDAQ:DNTH) Head-To-Head AnalysisApril 28, 2025 | americanbankingnews.comPrelude Announces Presentations at 2025 AACR Annual MeetingApril 25, 2025 | globenewswire.comSee More Prelude Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prelude Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prelude Therapeutics and other key companies, straight to your email. Email Address About Prelude TherapeuticsPrelude Therapeutics (NASDAQ:PRLD), a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.View Prelude Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be CautiousMeta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2Palantir Earnings: 1 Bullish Signal and 1 Area of ConcernMicrosoft Crushes Earnings, What’s Next for MSFT Stock?Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay AwayAMD Stock Signals Strong Buy Ahead of EarningsAmazon's Earnings Will Make or Break the Stock's Comeback Upcoming Earnings Palantir Technologies (5/5/2025)Vertex Pharmaceuticals (5/5/2025)CRH (5/5/2025)Realty Income (5/5/2025)Williams Companies (5/5/2025)American Electric Power (5/6/2025)Advanced Micro Devices (5/6/2025)Marriott International (5/6/2025)Constellation Energy (5/6/2025)Arista Networks (5/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.